About The Event
inVentiv Health is a global leader in Hematology and Oncology Research with unmatched skills and expertise. Schedule a meeting with us or stop by booth #21107 to learn more.
When:
June 2-6, 2107
Where:
McCormick Place
Chicago, IL
https://am.asco.org/
Booth #21107
Meet Our Clinical and Commercial Experts
Robert Millham
SVP & General Manager,
Hematology & Oncology
Joseph O'Connell, M.D.
VP & Therapeutic Area Head,
Hematology & Oncology
Dannelle Palmer
VP & Clinical Strategy Lead,
Hematology & Oncology
Dolores Tarabaric, M.D.
Executive Medical Director,
Hematology & Oncology
Theresa Bayt, M.D.
Senior Medical Director,
Hematology & Oncology
Richard Parra, RN
Director, Program Delivery,
Hematology & Oncology
Carlyle St. Paul, M.D.
Medical Director,
Hematology & Oncology
Hideyuki Ito, M.D.
Medical Director,
Oncology
Vasily Andrianov, M.D.
Medical Director,
Oncology
Firdavs Abdusamatov, M.D.
Medical Director,
Oncology
David Querry
President,
NAVICOR
Joe Daley
President, Addison Whitney
Chief Strategic Officer, inVentiv Health
Rafael Garza
Managing Director
Medical Communications
Lucy Rose
EMEA Lead
Patient Recruitment & Communications
Jessica Lee, PhD
Director, Commercial
Strategy & Planning,
inVentiv Health Consulting
Stephen Chang
Managing Director
Commercial Strategy & Planning
inVentiv Health Consulting
inVentiv Health by the Numbers
> 15,000 inVentiv Health Experts
helping global clients realize their goals in clinical development and commercialization.
> 90 Countries  
in which inVentiv Health has the ability to support clients.
550 Global Pharmaceutical Companies
have turned to inVentiv Health for expertise, skills and insight.
inVentiv Health is one of the nation’s largest providers of direct-to-patient communcations with real-time access to 9 years of data that includes:
30,000 Pharmacies
194M+ Health Consumers
285,000 Physicians
2.2 Billion Annual Prescriptions
60% of all retail prescriptions
across 35 chains
In the past 5 years, inVentiv Health
has helped to develop or commercialize:
Approved by the FDA
82%
Novel New Drugs
82%
Novel New Oncology Drugs
93%
Novel New Central Nervous System Drugs
Approved by the EMA
70%
Products Granted Marketing Authorization
81%
Oncology Drugs
67%
Central Nervous Systems Drugs